Allervie Clinical Research

Birmingham, Alabama 35209

6 studies enrolling now · 24 studies all time

What they study most

Allergic Reaction, Allergy, Allergy, Peanut, Atopic, Atopic Dermatitis, Chronic Inducible Urticaria, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Chronic Spontaneous Urticaria, Chronic Spontaneous Urticaria (CSU), Clonal Mast Cell Disease, Dermatitis, Dermatitis, Atopic

Studies at this site

• A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) — Recruiting now
• A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — Recruiting now
• A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines — Recruiting now
• Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations — Recruiting now
• A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — Recruiting now
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Recruiting now
• Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) — Running, not enrolling
• Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) — Running, not enrolling
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of DESF in Pediatric Subjects — Completed
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma — Running, not enrolling
• Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts — Completed
• A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines — Running, not enrolling
• A Study of CDX-0159 in Patients With Eosinophilic Esophagitis — Completed
• A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema — Completed
• A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) — Completed
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib — Running, not enrolling
• Long-term Extension Study of Ligelizumab in Food Allergy — Stopped early
• Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria — Stopped early
• Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis — Completed
• A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema — Running, not enrolling
• Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy — Stopped early
• A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. — Completed
• A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema — Running, not enrolling
• CNP-201 in Subjects With Peanut Allergy — Stopped early